James Robinson, CEO of A2 Biotherapeutics. (courtesy photo) Established in 2018, Agoura Hills-based A2 Biotherapeutics is developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells. The clinical-stage cell therapy company on Jan. 9 announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
